Video

Why would specialists use biosimilars? Can you discuss how rheumatologists and pharmacists make cost reduction-based clinical decisions when selecting anti-TNF biologics in the setting of RA, AS, psoriatic arthritis and related conditions?

Name: Why would specialists use biosimilars? Can you discuss how rheumatologists and pharmacists make cost reduction-based clinical decisions when selecting anti-TNF biologics in the setting of RA, AS, psoriatic arthritis and related conditions?
Uploaded: 2018-06-06T00:00:00+00:00
Description: Why would specialists want to use biosimilars in their practice? Can you discuss how rheumatologists and pharmacists should make important cost reduction-based clinical decisions when selecting anti-TNF biologics, based on primary differences between biosimilar therapies and their reference biologic agents in the setting of RA, AS, psoriatic arthritis and related conditions?

Published: June 6, 2018

Why would specialists use biosimilars? Can you discuss how rheumatologists and pharmacists make cost reduction-based clinical decisions when selecting anti-TNF biologics in the setting of RA, AS, psoriatic arthritis and related conditions?

Why would specialists want to use biosimilars in their practice? Can you discuss how rheumatologists and pharmacists should make important cost reduction-based clinical decisions when selecting anti-TNF biologics, based on primary differences between biosimilar therapies and their reference biologic agents in the setting of RA, AS, psoriatic arthritis and related conditions?

Overview

CLICK HERE FOR CME CREDIT

Created by

Presenter

Leonard Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute

Related Videos

Video

What clinical scenarios and patient types with RA and related diseases can you imagine where the use of a biosimilar-- INFLIXIMAB-DYYB or others--makes good pharmacoeconomic and clinical sense?

What clinical scenarios and patient types with RA and related diseases can you imagine where the use of a biosimilar— INFLIXIMAB-DYYB or others—makes good pharmacoeconomic and clinical sense, as opposed to using the reference brand product, ...

Video

Once analytics, pharmacokinetics, pharmacodynamics, and clinical trials confirm the clinical value and safety of the biosimilar, how does this translate into cost savings?

Once robust analytics, pharmacokinetics, pharmacodynamics, and clinical trials confirm the clinical value and safety of the biosimilar, how does this translate into cost savings for patients and healthcare institutions?

Video

After physicochemical criteria are met, what kind of clinical trials, with what end points and safety profiles must be achieved for regulatory agencies to approve biosimilars?

After physicochemical criteria are met, what kind of clinical trials, with precisely what end points and safety profiles must be achieved for regulatory agencies to approve biosimilars, and for what range of indications can such approvals be made?

Video

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications?

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications? Can you differentiate based on the specific steps of the approval process, evaluation, clinical trials required, ...

Video

Can you discuss study design, rationale, results, and implications of recent trials focused on anti-TNF biosimilars in the setting of RA, AS, and related conditions?

Can you discuss and explain the study design, rationale, results, and clinical implications of the most recent clinical evidence — i.e. clinical trials — focused on the safety and efficacy of approved biosimilar therapies, such as INFLIXIMAB-DYYB ...